FDA notifications. ESAs--serious cardiovascular complications.
D002319:Cardiovascular System / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D019983:Guideline Adherence; D016298:Hematopoietic Cell Growth Factors / Q000009:adverse effects*; D006801:Humans; D014481:United States
D016298:Hematopoietic Cell Growth Factors